What is Gracell Biotechnologies Inc. (GRCL)?

Gracell Biotechnologies Inc. (GRCL) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of GRCL?

The current price of GRCL is $10.25. Prices are updated in real time on Stocks360.

What is GRCL's price-to-earnings (PE) ratio?

GRCL's trailing twelve-month PE ratio is -1.52, based on current price and earnings per share data available on Stocks360.

What is GRCL's market capitalization?

GRCL's market capitalization is $197,973,420.00, placing it in the small-cap tier.

Gracell Biotechnologies Inc. (GRCL)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$10.25

Market Cap

$197.97M

PE (TTM)

-1.52

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

-0.34

Day Range

$10.17 – $10.28

52-wk Range

$1.40 – $10.44

Avg Volume

N/A

Volume

6.37M

Gracell Biotechnologies Inc. (GRCL) is a publicly traded company in the Healthcare sector. Latest price: $10.25. Market cap $197.97M. Trailing PE -1.52. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Mar 11, 2024

EPS $-0.30 vs est. $-0.14

Missed by $0.16

Proprietary Signals

Signal snapshot temporarily unavailable.

About Gracell Biotechnologies Inc.

Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of cell-based therapies, primarily for cancer treatment, within the People's Republic of China. The company's leading investigational therapies include: GC012F: A FasTCAR-enhanced autologous CAR-T product designed to target both BCMA and CD19, currently undergoing Phase I clinical trials for multiple myeloma. GC019F: A FasTCAR-enabled CD19-directed autologous CAR-T therapy, which is progressing through Phase I trials for adult B-cell acute lymphoblastic leukemia (B-ALL) and is also in preclinical development for relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL). GC027: A TruUCAR-powered allogeneic CAR-T product targeting CD7, presently in Phase I clinical development for adult T-cell acute lymphoblastic leukemia. Additionally, Gracell's pipeline features: GC007g: A donor-derived allogeneic CAR-T cell therapy directed at CD19, currently in a Phase 1/2 registrational study for r/r B-ALL. GC502: An off-the-shelf, TruUCAR-enabled allogeneic CAR-T candidate engineered to target both CD19 and CD7, which is in Phase I trials for B-cell malignancies. Beyond…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-1.52×
P/S (TTM)	0.00×
P/B	0.67×
P/FCF (TTM)	-0.36×
EV / EBITDA	-0.09×
EV / Sales	0.00×
Earnings Yield	-65.66%
Free Cash Flow Yield	-275.72%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$48.04M
Net Income (TTM)	-$866.58M
Free Cash Flow (TTM)	-$3.63B
Net Debt	-$1.27B
Working Capital	$1.28B
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-37.93%
Return on Invested Capital	-39.90%